Cinolazepam[2] (marketed under the brand name Gerodorm)[3] is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.
Clinical data | |
---|---|
Trade names | Gerodorm |
AHFS/Drugs.com | cinolazepam |
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90–100% |
Metabolism | Hepatic |
Elimination half-life | 3.8 hours[1] |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C18H13ClFN3O2 |
Molar mass | 357.8 g·mol−1 |
3D model (JSmol) |
|
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
It was patented in 1978 and came into medical use in 1992.[4] Cinolazepam is not approved for sale in the United States or Canada.